Chengdu Olymvax Biopharmaceuticals Inc.
SHH: 688319.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Shaowen Fan
- Employees
- 470
- Headquarters
- Chengdu, China
- IPO year
- 2021
- Market cap
- CN¥14.2B
- Website
- https://www.olymvax.com
Loading 688319…
Loading profile data…Frequently asked questions about 688319
What does Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS) do?
Olymvax Biopharmaceuticals Inc. develops and supplies vaccines. The company offers vaccines for Tetanus, a deadly infectious disease that causes nervous system toxicity by toxigenic clostridium tetanus; and haemophilus influenzae type b. it also develops vaccines for Staphylococcus aureus, a pathogenic bacterium that causes hospital infection an...
Where does 688319.SS trade?
Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS) trades on the Shanghai Stock Exchange.
What sector is 688319.SS in?
Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Chengdu Olymvax Biopharmaceuticals Inc.?
Shaowen Fan is the chief executive officer of Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS).
Where is Chengdu Olymvax Biopharmaceuticals Inc. headquartered?
Chengdu Olymvax Biopharmaceuticals Inc. is headquartered in China.
Does 688319.SS pay a dividend?
Yes — Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS) paid a trailing twelve-month dividend of CNY 0.04 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 688319.SS go public?
Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS) completed its initial public offering in 2021.